Seagen, a biotech company based in Bothell, Washington, is partnering up with Sanofi to develop and commercialize antibody-drug conjugates (ADCs) for up to three cancer targets. The companies will work together to co-fund the development costs and share profits generated from commercialization.
ADCs are a cancer therapy that target specific proteins in a cancer cell to strike tumors while sparing healthy cells. Seagen is well-established in ADCs, with experience advancing this type of therapy through clinical development and regulatory approvals.
The company currently has four approved ADCs, including a recent treatment for cervical cancer in collaboration with Genmab.